𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Screening for ESR mutations in breast and ovarian cancer patients

✍ Scribed by Tone Ikdahl Andersen; Richard Wooster; Kirsten Laake; Nadine Collins; William Warren; Martina Skrede; Rose Eeles; Kjell M. Tveit; Stephen R. D. Johnston; Mitchell Dowsett; Anne O. Olsen; Pål Møller; Mike R. Stratton; Anne-Lise Børresen-Dale

Publisher
John Wiley and Sons
Year
1997
Tongue
English
Weight
201 KB
Volume
9
Category
Article
ISSN
1059-7794

No coin nor oath required. For personal study only.

✦ Synopsis

In the present study, leukocyte DNA from 143 patients with familial clustering of breast and/or ovarian cancer and tumour DNA from 96 breast carcinomas were screened for base mutations in the estrogen receptor gene (ESR). Three patients with a family history of cancer were carrying a Gly160Cys germline substitution. This alteration was also detected in eight (four females and four males) of 729 controls (366 female, 363 males), indicating that the substitution probably represents a polymorphism. However, in the 229 female controls in whom family history of cancer was known, one of two who had a sister with breast cancer was carrying the variant allele. Hence, a possible clinical significance of the glycine into cysteine cannot be completely ruled out and should be further investigated. Somatic mutations were not detected in any of the tumours studied, and the present data do not provide support for somatic ESR base mutations as an important mechanism for hormonal therapy resistance in estrogen receptor-positive breast carcinomas. Hum. Mutat. 9:531-536, 1997.

📜 SIMILAR VOLUMES

BRCA1 mutation analysis in 83 Spanish br
BRCA1 mutation analysis in 83 Spanish breast and breast/ovarian cancer families
✍ Orland Díez; Joan Cortés; Montserrat Domènech; Joan Brunet; Elisabeth Del Río; C 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 French ⚖ 142 KB 👁 2 views

A group of 83 Spanish BC/OC families were analysed for BRCA1 germ-line mutations. Analysis of the entire coding sequence was carried out by SSCP and PTT. We identified 5 frameshift mutations: 185delAG (2 times), 189insTGTC, 1241delAC, and 5537delA and 3 missense mutations in BRCA1: 330A G G, 1240C G

Prevalence of founder BRCA1 and BRCA2 mu
Prevalence of founder BRCA1 and BRCA2 mutations among breast and ovarian cancer patients in hungary
✍ Marco Van der Looij; Csilla Szabo; Istvan Besznyak; Gyorgy Liszka; Bela Csokay; 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 French ⚖ 55 KB 👁 2 views

We have investigated the impact of BRACA1 and BRACA2 mutations that were frequently identified among Hungarian high-risk breast-ovarian cancer families (Ramus et al., 1997b, AJHG), on the development of breast and ovarian cancer in the general Hungarian population. The prevalence of 3 BRCA1 mutation

Patients' attitudes about autonomy and c
Patients' attitudes about autonomy and confidentiality in genetic testing for breast-ovarian cancer susceptibility
✍ Benkendorf, Judith L.; Reutenauer, Jeri E.; Hughes, Chanita A.; Eads, Nadine; Wi 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 40 KB 👁 2 views

The identification of BRCA1 and BRCA2, two breast-ovarian cancer susceptibility genes, has brought many ethical and social issues to the forefront. This paper presents the results of a survey assessing the attitudes of 238 unaffected first-degree relatives of women with breast or ovarian cancer rega

A highly sensitive, fast, and economical
A highly sensitive, fast, and economical technique for mutation analysis in hereditary breast and ovarian cancers
✍ Norbert Arnold; Eva Gross; Ulrike Schwarz-Boeger; Jacobus Pfisterer; Walter Jona 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 238 KB 👁 1 views

## Communicated by Albert de la Chapelle Mutation analysis of complex genes without hotspots for sequence variations, such as BRCA1, is time-consuming and expensive. Of all currently available methods, direct sequencing has the highest sensitivity, but also the highest costs. Other techniques, such

BRCA1-related breast cancer in Austrian
BRCA1-related breast cancer in Austrian breast and ovarian cancer families: Specific BRCA1 mutations and pathological characteristics
✍ Teresa M. U. Wagner; Regine A. Möslinger; Daniela Muhr; Gudrun Langbauer; Kora H 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 French ⚖ 76 KB 👁 2 views

We identified 17 BRCA1 mutations in 86 Austrian breast and ovarian cancer families (20%) that were screened for mutations by denaturing high-performance liquid chromatography (DHPLC) and the protein truncation test (PTT). Eleven distinct mutations were detected, 4 of them (962del4, 2795del4, 3135del